Welcome to our dedicated page for Aclarion news (Ticker: ACON), a resource for investors and traders seeking the latest updates and insights on Aclarion stock.
Aclarion, Inc. develops healthcare technology for chronic low back pain through Nociscan, a cloud-based SaaS platform that uses magnetic resonance spectroscopy, biomarkers, signal processing and augmented intelligence algorithms to help physicians evaluate painful and nonpainful lumbar discs.
Company news commonly covers Nociscan adoption, clinical-site additions, commercial agreements with spine practices and academic medical centers, reimbursement activity, intellectual-property updates for AI-enabled workflows, and operating results. Updates also include capital actions and governance items tied to Aclarion’s Nasdaq-listed common stock and warrants.
Aclarion (Nasdaq: ACON) reported that its Nociscan platform for chronic low back pain is now available at Goodman Campbell Brain & Spine at Ascension St. Vincent, the first site in Indiana to offer the technology. This extends Aclarion’s provider network into a new state and connects the Company with a neurosurgery and spine care center recognized nationally for clinical excellence, training, and research. Nociscan uses Magnetic Resonance Spectroscopy to quantify chemical biomarkers associated with disc pain, helping physicians distinguish between painful and nonpainful lumbar discs and offering objective, non-invasive insights that MRI alone cannot provide. According to Aclarion, Nociscan demonstrates a 97% surgical success rate when all Nociscan-positive discs are treated.
Aclarion (Nasdaq: ACON) released a CEO shareholder letter outlining operational and financial progress for the first half of 2026. The company reported 141% year-over-year and 71% sequential scan volume growth, indicating increased clinical use of its Nociscan technology in spine care workflows.
According to Aclarion, Nociscan utilization expanded across commercial accounts in the U.S. and U.K., supported by U.K. reimbursement from Vitality, AXA, and Aviva. Aclarion launched a U.S. Market Access Program with PRIA Healthcare to pursue payer coverage. The company also highlighted progress toward the CLARITY trial readout, added a new AI-focused patent for a total of 65 issued and pending patents, and reported a $16.3 million cash balance with no debt as of June 30, 2026, providing cash runway into the second half of 2027.
Aclarion (Nasdaq: ACON) announced that two abstracts featuring its Nociscan SaaS platform were presented at the American Society of Pain & Neuroscience (ASPN) Annual Meeting in Miami, Florida. The work focuses on using MR Spectroscopy (MRS) to improve identification of painful lumbar discs in chronic low back pain.
The first abstract outlines a 20‑patient prospective real‑world evidence study integrating Nociscan with standard MRI for intradiscal treatment planning, with early results showing successful workflow incorporation and concluding that MRS is a noninvasive tool with “immense utility” in clinical practice. The second abstract reports a basivertebral nerve ablation case in a 69‑year‑old patient without classic Modic changes, where Nociscan-guided level selection preceded a reported 95% pain relief two weeks post‑procedure. Aclarion notes Nociscan quantifies disc pain–associated biomarkers and cites a 97% surgical success rate when all Nociscan‑positive discs are treated.
Aclarion (Nasdaq: ACON) added Texas Spine Care Center, a high-volume orthopedic spine practice in San Antonio, as a new clinical site in its CLARITY randomized trial of Nociscan for discogenic chronic low back pain.
CLARITY plans to enroll 300 surgical patients, measures 12‑month VAS back pain as the primary endpoint, and targets an initial internal readout and early interim public results in Q4 2026. According to Aclarion, Nociscan uses MR Spectroscopy and AI to distinguish painful from nonpainful lumbar discs and has shown a 97% surgical success rate when all Nociscan‑positive discs are treated.
Aclarion (Nasdaq: ACON) will present at Planet MicroCap Las Vegas 2026 Powered by MicroCapClub on June 17, 2026, at 8:30 AM PT at the Bellagio Resort & Hotel. Executive Chairman Jeff Thramann will host the session and answer investor questions.
According to Aclarion, recent highlights include triple-digit annual Nociscan growth, progress on reimbursement and the CLARITY trial with an interim readout expected in Q4 2026, an expanded AI patent portfolio totaling 64 issued and pending patents, a $2.5 million share repurchase program, and a debt-free balance sheet with cash runway into the second half of 2027.
Investors can access the live webcast via the event link and schedule in-person 1x1 meetings at the Bellagio by registering through the conference platform. Archived webcasts will be available under the Agenda tab on the Planet MicroCap Las Vegas 2026 site.
Aclarion (Nasdaq: ACON) launched a Market Access Program with PRIA Healthcare to advance reimbursement and U.S. commercial adoption of its AI-powered Nociscan platform for chronic low back pain.
The partnership targets payer engagement, prior authorization support, appeals management, and builds on payer approvals already achieved with major UK insurers.
Aclarion (Nasdaq: ACON) announced that its Board unanimously rejected Echo Lake Capital’s unsolicited public proposal to acquire the company at $4.00 per share. The Board believes the offer undervalues Aclarion, relies on its cash to finance the acquisition, and would disproportionately benefit Echo Lake. The Board remains open to proposals that appropriately reflect Aclarion’s intrinsic value, strategic assets and long-term potential.
Aclarion (Nasdaq: ACON) reported that stockholders approved all proposals at the 2026 annual meeting held June 4, 2026. Approvals covered electing seven directors through the 2027 meeting, ratifying Haynie & Company as auditor, and amending the 2022 equity incentive plan.
Aclarion highlighted 196% year-over-year growth in Q1 2026 Nociscan scan volumes, expanded insurance coverage in the United Kingdom, and progress in its United States reimbursement strategy for its AI-driven chronic low back pain assessment technology.
Aclarion (Nasdaq: ACON) entered an agreement with the Institute of Neuro Innovation (INI) in Los Angeles, expanding access to its Nociscan platform for chronic low back pain patients.
The collaboration will generate real-world evidence combining Nociscan’s pain-related chemical biomarker data with SPECT-CT bone metabolic information, supporting Aclarion’s scalable growth strategy and payer and provider adoption. Nociscan is described as a SaaS tool that helps distinguish painful from nonpainful lumbar discs and has demonstrated a 97% surgical success rate when all Nociscan-positive discs are treated.
Aclarion (Nasdaq:ACON) reported that its Nociscan MRS technology was used in an NIH-funded, ISSLS Best Paper Award study on chronic low back pain with Modic type 1 changes.
By measuring intradiscal propionic acid, researchers identified immune-linked patient subgroups, suggesting potential Nociscan uses beyond surgical decision support in precision spine care.